E L Eisenstein

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Economic analysis of endovascular repair versus surveillance for patients with small abdominal aortic aneurysms
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Electronic address
    J Vasc Surg 58:302-10. 2013
  2. doi request reprint Evaluating the impact of public health notification: Duke clopidogrel experience
    Eric L Eisenstein
    Duke Clinical Research Institute and Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 5:767-74. 2012
  3. ncbi request reprint Population-based clinical decision support: a clinical and economic evaluation
    Eric L Eisenstein
    Duke University Medical Center, Durham, NC, USA
    Stud Health Technol Inform 180:343-7. 2012
  4. pmc Economics methods in Cochrane systematic reviews of health promotion and public health related interventions
    Ian Shemilt
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    BMC Med Res Methodol 6:55. 2006
  5. doi request reprint Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 2:1178-87. 2009
  6. doi request reprint DRIVE it home: making the case for prospective economic data collection in randomized clinical trials
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Kidney Int 74:1507-9. 2008
  7. pmc Impact of the Patient-Reported Outcomes Management Information System (PROMIS) upon the design and operation of multi-center clinical trials: a qualitative research study
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    J Med Syst 35:1521-30. 2011
  8. doi request reprint Nonfatal myocardial infarction and long-term outcomes in coronary artery disease
    Eric L Eisenstein
    Duke Clinical Research Institute, Outcomes, Durham, NC 27705, USA
    Am Heart J 163:95-103. 2012
  9. doi request reprint Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 2:1199-207. 2009
  10. ncbi request reprint Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure
    Eric L Eisenstein
    Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 143:1112-7. 2002

Detail Information

Publications41

  1. doi request reprint Economic analysis of endovascular repair versus surveillance for patients with small abdominal aortic aneurysms
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Electronic address
    J Vasc Surg 58:302-10. 2013
    ..We evaluated resource use, medical cost, and quality of life outcomes associated with the PIVOTAL treatment strategies...
  2. doi request reprint Evaluating the impact of public health notification: Duke clopidogrel experience
    Eric L Eisenstein
    Duke Clinical Research Institute and Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 5:767-74. 2012
    ..We evaluated whether public health interventions were associated with changes in patient-reported clopidogrel use among DES patients...
  3. ncbi request reprint Population-based clinical decision support: a clinical and economic evaluation
    Eric L Eisenstein
    Duke University Medical Center, Durham, NC, USA
    Stud Health Technol Inform 180:343-7. 2012
    ....
  4. pmc Economics methods in Cochrane systematic reviews of health promotion and public health related interventions
    Ian Shemilt
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    BMC Med Res Methodol 6:55. 2006
    ....
  5. doi request reprint Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 2:1178-87. 2009
    ..This study was designed to evaluate long-term clinical and economic outcomes for subjects receiving Endeavor drug-eluting versus Driver bare-metal stents (both Medtronic CardioVascular, Santa Rosa, California)...
  6. doi request reprint DRIVE it home: making the case for prospective economic data collection in randomized clinical trials
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Kidney Int 74:1507-9. 2008
    ....
  7. pmc Impact of the Patient-Reported Outcomes Management Information System (PROMIS) upon the design and operation of multi-center clinical trials: a qualitative research study
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    J Med Syst 35:1521-30. 2011
    ..The requirements identified in this study serve as a framework for future investigators in the design, development, implementation, and operation of PROMIS Tool Kit technologies...
  8. doi request reprint Nonfatal myocardial infarction and long-term outcomes in coronary artery disease
    Eric L Eisenstein
    Duke Clinical Research Institute, Outcomes, Durham, NC 27705, USA
    Am Heart J 163:95-103. 2012
    ..We sought to estimate the long-term clinical implications of nonfatal MI occurring within the first 3 and 6 months after initial cardiac catheterization...
  9. doi request reprint Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 2:1199-207. 2009
    ....
  10. ncbi request reprint Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure
    Eric L Eisenstein
    Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 143:1112-7. 2002
    ..They also had significantly fewer serious cardiac adverse events...
  11. ncbi request reprint Economic assessment of thrombocytopenia: CATCH Registry
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    J Med Syst 34:379-86. 2010
    ..001); and (group 3) (difference, $27,077; 95% CI, $22,901-$31,252; P<.001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences...
  12. doi request reprint Re-evaluating the volume-outcome relationship in hemodialysis patients
    Eric L Eisenstein
    Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Durham, NC 27705, USA
    Health Policy 88:317-25. 2008
    ..We sought to determine whether dialysis patient mortality rates are associated with differences in dialysis facility size, and whether this relationship differs among higher risk diabetic and lower-risk non-diabetic patients...
  13. ncbi request reprint The use of patient mix-adjusted control charts to compare in-hospital costs of care
    E L Eisenstein
    Duke University Medical Center, Durham, NC 27710, USA
    Health Care Manag Sci 2:193-8. 1999
    ..After adjustment, two months had average costs outside the 90% lower control limit lines, and the trend toward increasing costs had been explained by differences in patient acuity...
  14. ncbi request reprint Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eric L Eisenstein
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 297:159-68. 2007
    ..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
  15. pmc Assessing the economic attractiveness of coronary artery revascularization in chronic kidney disease patients
    Eric L Eisenstein
    Duke University Medical Center, Durham, NC 27715, USA
    J Med Syst 33:287-97. 2009
    ..Medical therapy was an economically attractive strategy vs. CABG surgery or PCI for three-vessel CAD patients with CKD, two-vessel CAD patients without CKD, and all single-vessel CAD patients...
  16. ncbi request reprint Cost effectiveness of early discharge after uncomplicated acute myocardial infarction
    L K Newby
    Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    N Engl J Med 342:749-55. 2000
    ..Reducing the length of hospitalizations can reduce short-term costs, but there are few data on the long-term clinical and economic consequences of early discharge...
  17. ncbi request reprint Assessing the clinical and economic burden of coronary artery disease: 1986-1998
    E L Eisenstein
    Outcomes Research and Assessment Group, The Duke Clincal Research Institute, Durham, NC, USA
    Med Care 39:824-35. 2001
    ..We compared the clinical and economic burden of CAD during the acute phase (first 30 days) with that in the postacute phase (31st day through 10 years)...
  18. ncbi request reprint Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndrome
    E L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Pharmacoeconomics 17:263-72. 2000
    ..To evaluate the relationship between how much a new cardiovascular therapy improves clinical outcomes over current therapies and how much more it can cost while still remaining 'economically attractive'...
  19. ncbi request reprint Advanced coronary artery disease: Appropriate end points for trials of novel therapies
    D E Kandzari
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 142:843-51. 2001
    ..Because the natural history of these patients is less defined, the appropriate end points for trials of novel revascularization therapies involving patients with advanced coronary artery disease are not certain...
  20. ncbi request reprint Obesity and long-term clinical and economic outcomes in coronary artery disease patients
    Eric L Eisenstein
    The Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Obes Res 10:83-91. 2002
    ..We assessed the impact of increasing body mass index (BMI) on 10-year outcomes for ACS patients...
  21. doi request reprint Long-term clinical outcomes following coronary stenting
    Kevin J Anstrom
    Department of Biostatistics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:1647-55. 2008
    ..The objective of this study was to compare the long-term clinical outcomes of patients receiving DES vs BMS in a clinical practice setting...
  22. ncbi request reprint Late adverse events after drug-eluting stent implantation
    David F Kong
    Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27710, USA
    Curr Cardiol Rep 10:253-62. 2008
    ..This timely, robust evidence base reflects an alignment of academic, industry, and public health priorities...
  23. ncbi request reprint Outcomes of second revascularization procedures after stent implantation
    Richard P Konstance
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    J Med Syst 32:177-86. 2008
    ..Further studies are needed to determine the optimum application for CABG vs. DES as a second or third revascularization procedure...
  24. doi request reprint Sensible approaches for reducing clinical trial costs
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Clin Trials 5:75-84. 2008
    ..Over the past decade, annual funding for biomedical research has more than doubled while new molecular entity approvals have declined by one third...
  25. doi request reprint Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 155:369-74. 2008
    ..We sought to determine the relationship between bleeding, blood transfusion, and measures of costs among patients with non-ST-segment elevation ACS...
  26. ncbi request reprint Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases
    Lesley H Curtis
    Duke Clinical Research Institute, and Departments of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
    Med Care 45:S103-7. 2007
    ..Finally, we offer detailed guidance about how to implement the estimators in comparative effectiveness analyses...
  27. ncbi request reprint Economic impact of drug-eluting stents on hospital systems: a disease-state model
    David F Kong
    Duke Clinical Research Institute, DUMC, Durham, NC 27710, USA
    Am Heart J 147:449-56. 2004
    ..The US Department of Health and Human Services (HHS), recognizing the financial and clinical impact of this technology, recently proposed accelerated reimbursement to hospitals...
  28. ncbi request reprint A problem-based approach to teaching outcomes research in family medicine residency
    Truls Ostbye
    Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27110, USA
    Fam Med 36:470-2. 2004
    ..This study's objective was to introduce research concepts and skills in family medicine residency through a problem-based course...
  29. ncbi request reprint Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II
    Sana M Al-Khatib
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Ann Intern Med 142:593-600. 2005
    ..3 or less...
  30. ncbi request reprint Reducing the costs of phase III cardiovascular clinical trials
    Eric L Eisenstein
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 149:482-8. 2005
    ..1 billion dollars in cardiovascular products). We compared pharmaceutical companies' planned resource use and costs in Phase III cardiovascular trials and identified cost-saving strategies...
  31. ncbi request reprint Surgeons' economic profiles: can we get the "right" answers?
    Eric L Eisenstein
    Outcomes Research and Assessment Group, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, 27715 7969, USA
    J Med Syst 29:111-24. 2005
    ..Adjusting for patient-mix differences and treating surgeons as random effects was the preferred approach. These results demonstrate the need for hospitals to reexamine their economic profiling methods...
  32. ncbi request reprint Decision models for assessing the cost effectiveness of drug-eluting stents
    David F Kong
    Duke University Medical Centre, Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27710, USA
    Expert Opin Pharmacother 6:965-74. 2005
    ..More research is recommended to identify high-risk patients who stand to gain significant health benefits from this therapy...
  33. ncbi request reprint Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction
    Padma Kaul
    Department of Medicine, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 149:637-44. 2005
    ....
  34. ncbi request reprint Local cost structures and the economics of robot assisted radical prostatectomy
    Charles D Scales
    Division of Urology, Department of Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA
    J Urol 174:2323-9. 2005
    ..We investigated the sensitivity of RAP and RRP inpatient costs to variations in length of stay (LOS), local hospitalization costs and robotic case volume in the specialist and generalist settings...
  35. ncbi request reprint Conducting an economic analysis to assess the electrocardiogram's value
    Eric L Eisenstein
    Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27715, USA
    J Electrocardiol 39:241-7. 2006
    ..Health economic analyses seek to assess the relative value (cost vs health benefit trade-offs) of medical technologies. However, these methods have been underused in studies of the electrocardiogram (ECG)...
  36. ncbi request reprint What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial
    Eric L Eisenstein
    The Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Card Fail 12:336-42. 2006
    ..At 37 months average follow-up, patients in both groups had similar mortality. We determined the incremental costs associated with the use of digoxin in this high-risk population...
  37. ncbi request reprint Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes
    Eric L Eisenstein
    Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 118:981-90. 2005
    ..We evaluated the relationship between elevated body mass index (BMI) and 30-day, 90-day, and 1-year clinical outcomes postacute coronary syndromes...
  38. pmc Economic return of clinical trials performed under the pediatric exclusivity program
    Jennifer S Li
    Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA
    JAMA 297:480-8. 2007
    ..This critique has been a substantial part of congressional debate on the program, which is due to expire in 2007...
  39. ncbi request reprint Problem-based learning of research skills
    Thomas H Davis
    Duke University Medical Center, Durham, NC 27705, USA
    J Electrocardiol 39:120-8. 2006
    ..To determine whether a short-term, problem-based educational intervention leads to increased research activity among health care practitioners...
  40. ncbi request reprint Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international pilot study
    Hope E Buell
    The Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, North Carolina, USA
    J Med Syst 26:293-300. 2002
    ....
  41. pmc The economic returns of pediatric clinical trials of antihypertensive drugs
    Carissa M Baker-Smith
    Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    Am Heart J 156:682-8. 2008
    ..We sought to determine the cost of performing pediatric exclusivity trials within a single therapeutic area and the subsequent economic return to industry sponsors...